CAPR analyst estimates
Capricor (CAPR) analyst ratings, the average price target and its range, and every firm's latest call.
CAPR analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 14, 2026 | B.Riley Financial | B.Riley Upgrades Capricor Therapeutics (CAPR) to Buy | $21.00 |
| Sep 1, 2026 | Piper Sandler | Capricor Therapeutics upgraded to Overweight from Neutral at Piper Sandler | $25.00 |
| Jul 29, 2026 | Cantor Fitzgerald | Capricor downgraded to Neutral from Overweight at Cantor Fitzgerald | $3.50 |
| Jul 28, 2026 | Industrial Alliance Securities | Capricor Therapeutics downgraded to Neutral from Buy at Alliance Global | $7.00 |
| Jul 27, 2026 | Roth Capital | Capricor Therapeutics downgraded to Neutral from Buy at Roth Capital | $7.00 |
| May 15, 2026 | Roth Capital | Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital | $38.00 |
| Mar 13, 2026 | Cantor Fitzgerald | Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald After Q4 Result | $62.00 |
| Dec 15, 2025 | UBS | Capricor Therapeutics price target raised to $50 from $21 at B. Riley | $50.00 |
| Dec 10, 2025 | Piper Sandler | Capricor Therapeutics price target raised to $45 from $20 at Piper Sandler | $45.00 |
| Dec 8, 2025 | Oppenheimer | Capricor Therapeutics price target raised to $54 from $22 at Oppenheimer | $54.00 |
| Dec 4, 2025 | Maxim Group | Capricor Therapeutics price target raised to $50 from $25 at Maxim | $50.00 |
| Dec 3, 2025 | H.C. Wainwright | Capricor Therapeutics price target raised to $60 from $24 at H.C. Wainwright | $60.00 |
| Dec 3, 2025 | Industrial Alliance Securities | Capricor Therapeutics price target raised to $48 from $16 at Alliance Global | $48.00 |
| Nov 11, 2025 | Roth Capital | Capricor Therapeutics price target raised to $13 from $12 at Roth Capital | $13.00 |
| Jul 11, 2025 | Piper Sandler | Capricor Therapeutics price target lowered to $20 from $43 at Piper Sandler | $20.00 |
- 8 firms rate CAPR: 6 buy, 2 hold, 0 sell.
- The average price target is $12.70 from 5 analysts, from $3.50 to $25.00.
Updated 2026-11-02 23:10 UTC